Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 22.1% in February

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 344,000 shares, a growth of 22.1% from the February 13th total of 281,700 shares. Based on an average daily volume of 236,200 shares, the days-to-cover ratio is currently 1.5 days. Currently, 7.5% of the company’s shares are sold short.

Vivos Therapeutics Stock Up 8.5 %

Shares of VVOS opened at $3.58 on Tuesday. Vivos Therapeutics has a 52-week low of $1.91 and a 52-week high of $6.28. The firm has a 50-day moving average price of $4.06 and a 200 day moving average price of $3.57. The firm has a market capitalization of $21.09 million, a PE ratio of -0.63 and a beta of 7.47.

Analyst Ratings Changes

Several equities research analysts have commented on VVOS shares. Alliance Global Partners lowered their price objective on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Ascendiant Capital Markets reissued a “buy” rating and issued a $6.60 target price on shares of Vivos Therapeutics in a report on Wednesday, November 20th.

Hedge Funds Weigh In On Vivos Therapeutics

Large investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC boosted its position in shares of Vivos Therapeutics by 23.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,000 shares of the company’s stock valued at $112,000 after purchasing an additional 5,000 shares in the last quarter. Cutter & CO Brokerage Inc. purchased a new stake in Vivos Therapeutics during the fourth quarter valued at about $163,000. Geode Capital Management LLC lifted its stake in Vivos Therapeutics by 55.6% during the fourth quarter. Geode Capital Management LLC now owns 44,827 shares of the company’s stock valued at $192,000 after buying an additional 16,025 shares in the last quarter. Finally, Anson Funds Management LP purchased a new stake in Vivos Therapeutics during the fourth quarter valued at about $1,041,000. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.